GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARsgen Therapeutics Holdings Ltd (HKSE:02171) » Definitions » Cash Flow from Financing

CARsgen Therapeutics Holdings (HKSE:02171) Cash Flow from Financing : HK$19.93 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is CARsgen Therapeutics Holdings Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2024, CARsgen Therapeutics Holdings paid HK$0.00 Mil more to buy back shares than it received from issuing new shares. It received HK$0.00 Mil from issuing more debt. It paid HK$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received HK$0.00 Mil from paying cash dividends to shareholders. It received HK$0.00 Mil on other financial activities. In all, CARsgen Therapeutics Holdings spent HK$0.00 Mil on financial activities for the six months ended in Dec. 2024.


CARsgen Therapeutics Holdings Cash Flow from Financing Historical Data

The historical data trend for CARsgen Therapeutics Holdings's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARsgen Therapeutics Holdings Cash Flow from Financing Chart

CARsgen Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Financing
Get a 7-Day Free Trial 1,543.99 3,274.27 -264.12 -24.22 19.71

CARsgen Therapeutics Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -254.12 -8.21 -16.01 26.58 -6.65

CARsgen Therapeutics Holdings Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

CARsgen Therapeutics Holdings's Cash from Financing for the fiscal year that ended in Dec. 2024 is calculated as:

CARsgen Therapeutics Holdings's Cash from Financing for the quarter that ended in Dec. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$19.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CARsgen Therapeutics Holdings  (HKSE:02171) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

CARsgen Therapeutics Holdings's issuance of stock for the six months ended in Dec. 2024 was HK$0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

CARsgen Therapeutics Holdings's repurchase of stock for the six months ended in Dec. 2024 was HK$0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

CARsgen Therapeutics Holdings's net issuance of debt for the six months ended in Dec. 2024 was HK$0.00 Mil. CARsgen Therapeutics Holdings received HK$0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

CARsgen Therapeutics Holdings's net issuance of preferred for the six months ended in Dec. 2024 was HK$0.00 Mil. CARsgen Therapeutics Holdings paid HK$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

CARsgen Therapeutics Holdings's cash flow for dividends for the six months ended in Dec. 2024 was HK$0.00 Mil. CARsgen Therapeutics Holdings received HK$0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

CARsgen Therapeutics Holdings's other financing for the six months ended in Dec. 2024 was HK$0.00 Mil. CARsgen Therapeutics Holdings received HK$0.00 Mil on other financial activities.


CARsgen Therapeutics Holdings Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of CARsgen Therapeutics Holdings's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


CARsgen Therapeutics Holdings Business Description

Traded in Other Exchanges
N/A
Address
No. 466 Yindu Road, Building 2, 1st Floor, Xuhui District, Shanghai, CHN
CARsgen Therapeutics Holdings Ltd is a clinical-stage biopharmaceutical company discovering, researching, and developing cell therapies in the People's Republic of China and the United States of America.
Executives
Bei Jing Shen Nong Tou Zi Guan Li Gu Fen You Xian Gong Si 2102 Investment manager
Candock Holdings Limited 2501 Other
Yi Jie Sheng Wu Ji Shu Kong Gu You Xian Gong Si 2501 Other
Yi De Kong Gu You Xian Gong Si 2501 Other
Quan Zhou Shi Ding Wo Chuang Feng Tou Zi Zhong Xin You Xian He Huo 2501 Other
Yang Xuehong 2501 Other
Wang Huamao 2401 A concert party to an agreement to buy shares
Li Zonghai 2401 A concert party to an agreement to buy shares
Guo Bingsen 2401 A concert party to an agreement to buy shares
Accure Biotech Limited 2501 Other
Cart Biotech Limited 2501 Other
Chen Haiou 2501 Other
Guo Xiaojing 2501 Other
He Xi Holdings Limited 2501 Other
Redelle Holding Limited 2501 Other

CARsgen Therapeutics Holdings Headlines

No Headlines